Your shopping cart is currently empty

Iptacopan hydrochloride (LNP023 hydrochloride) is an orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 of 10 nM. Iptacopan hydrochloride shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $52 | In Stock | In Stock | |
| 2 mg | $74 | In Stock | In Stock | |
| 5 mg | $123 | In Stock | In Stock | |
| 10 mg | $206 | In Stock | In Stock | |
| 25 mg | $372 | In Stock | In Stock | |
| 50 mg | $621 | In Stock | In Stock | |
| 100 mg | $1,030 | In Stock | In Stock | |
| 200 mg | $1,390 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $123 | In Stock | In Stock |
| Description | Iptacopan hydrochloride (LNP023 hydrochloride) is an orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 of 10 nM. Iptacopan hydrochloride shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM. |
| Targets&IC50 | FB:7.9 nM (KD), Membrane aTT cellsack Complex (MAC):130 nM, FB:10 nM |
| In vitro | LNP023 demonstrates excellent selectivity over other proteases affording IC50 values of >30 μM across a panel of 41 human proteases, including the AP protein factor D (>100 μM)[3]. |
| In vivo | LNP023 (20-180 mg/kg; oral administration) demonstrates efficacy in both prophylactic and therapeutic dosing in a rat model of membranous nephropathy and prevents KRN (150 μL)-induced arthritis in mice[2]. Following oral administration (rat 30 mg/kg, dog 10 mg/kg), LNP023 exhibits moderate half-lives (T1/2; Wistar Han rats 3.4 h, beagle dogs 5.5 h) and Cmax (Wistar Han rats 410 nM, beagle dogs 2200 nM)[3]. |
| Synonyms | LNP023 hydrochloride, Iptacopan HCl |
| Molecular Weight | 458.98 |
| Formula | C25H31ClN2O4 |
| Cas No. | 1646321-63-2 |
| Smiles | Cl.CCO[C@H]1CCN(Cc2c(OC)cc(C)c3[nH]ccc23)[C@@H](C1)c1ccc(cc1)C(O)=O |
| Relative Density. | no data available |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: 50 mg/mL (108.94 mM), Sonication and heating are recommended. DMSO: 252 mg/mL (549.04 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (10.89 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
H2O/DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.